Valneva SE (VLA.PA)
Makes vaccines for diseases like Japanese encephalitis, cholera, and chikungunya.
The outlook
Valneva is trading well below its recent moving averages and sits near the lower end of its 52-week range, reflecting weak near-term momentum. Analyst coverage shows a notably bullish average price target roughly 139% above the current price, though the stock's StockGlow score leans bearish overall. The wide gap between the depressed price and target suggests either significant upside potential or a disconnect between analyst expectations and current market sentiment.
What’s behind the score
Analyst price target
~12-month · 6 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.